Cunningham EB; Hajarizadeh B; Amin J; Litwin AH; Gane E; Cooper C; Lacombe K; Hellard M; Read P; Powis J; Dalgard O; Bruneau J; Matthews GV; Feld JJ; Dillon JF; Shaw D; Bruggmann P; Conway B; Fraser C; Marks P; Dore GJ; Grebely J, 2020, 'Adherence to once-daily and twice-daily direct-acting antiviral therapy for Hepatitis C infection among people with recent injection drug use or current opioid agonist therapy', Clinical Infectious Diseases, vol. 71, pp. E115 - E124, http://dx.doi.org/10.1093/cid/ciz1089
Martinello M; Yee J; Bartlett SR; Read P; Baker D; Post JJ; Finlayson R; Bloch M; Doyle J; Shaw D; Hellard M; Petoumenos K; Lin L; Marks P; Applegate T; Dore GJ; Matthews GV, 2020, 'Moving towards Hepatitis C microelimination among people living with human immunodeficiency virus in Australia: The CEASE study', Clinical Infectious Diseases, vol. 71, pp. 1502 - 1510, http://dx.doi.org/10.1093/cid/ciz985
Martinello M; Orkin C; Cooke G; Bhagani S; Gane E; Kulasegaram R; Shaw D; Tu E; Petoumenos K; Marks P; Grebely J; Dore GJ; Nelson M; Matthews GV, 2020, 'Short-Duration Pan-Genotypic Therapy With Glecaprevir/Pibrentasvir for 6 Weeks Among People With Recent Hepatitis C Viral Infection', Hepatology, vol. 72, pp. 7 - 18, http://dx.doi.org/10.1002/hep.31003
Artenie AA; Cunningham EB; Dore GJ; Conway B; Dalgard O; Powis J; Bruggmann P; Hellard M; Cooper C; Read P; Feld JJ; Hajarizadeh B; Amin J; Lacombe K; Stedman C; Litwin AH; Marks P; Matthews GV; Quiene S; Erratt A; Bruneau J; Grebely J, 2020, 'Patterns of drug and alcohol use and injection equipment sharing among people with recent injecting drug use or receiving opioid agonist treatment during and following hepatitis c virus treatment with directacting antiviral therapies: An international study', Clinical Infectious Diseases, vol. 70, pp. 2369 - 2376, http://dx.doi.org/10.1093/cid/ciz633
Grebely J; Read P; Cunningham EB; Weltman M; Matthews GV; Dunlop A; Montebello M; Martinello M; Gilliver R; Marks P; Applegate TL; Dore GJ, 2020, 'Elbasvir and grazoprevir for hepatitis C virus genotype 1 infection in people with recent injecting drug use (DARLO-C): An open-label, single-arm, phase 4, multicentre trial', Health Science Reports, vol. 3, pp. e151, http://dx.doi.org/10.1002/hsr2.151
Valerio H; Alavi M; Silk D; Treloar C; Martinello M; Milat A; Dunlop A; Holden J; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Hayllar J; Reid D; Gorton C; Lam T; Dore GJ; Grebely J, 2020, 'Progress towards elimination of hepatitis C infection among people who inject drugs in Australia: The ETHOS Engage Study.', Clin Infect Dis, http://dx.doi.org/10.1093/cid/ciaa571
Cunningham EB; Hajarizadeh B; Amin J; Hellard M; Bruneau J; Feld JJ; Cooper C; Powis J; Litwin AH; Marks P; Dalgard O; Conway B; Moriggia A; Stedman C; Read P; Bruggmann P; Lacombe K; Dunlop A; Applegate TL; Matthews GV; Fraser C; Dore GJ; Grebely J, 2020, 'Reinfection following successful direct-acting antiviral therapy for hepatitis C infection among people who inject drugs.', Clin Infect Dis, http://dx.doi.org/10.1093/cid/ciaa253
Dore GJ; Feld JJ; Thompson A; Martinello M; Muir AJ; Agarwal K; Müllhaupt B; Wedemeyer H; Lacombe K; Matthews GV; Schultz M; Klein M; Hezode C; Mercade GE; Kho D; Petoumenos K; Marks P; Tatsch F; Dos Santos AGP; Gane E, 2020, 'Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial', Journal of Hepatology, vol. 72, pp. 431 - 440, http://dx.doi.org/10.1016/j.jhep.2019.10.010
Bajis S; Grebely J; Hajarizadeh B; Applegate T; Marshall AD; Ellen Harrod M; Byrne J; Bath N; Read P; Edwards M; Gorton C; Hayllar J; Cock V; Peterson S; Thomson C; Weltman M; Jefferies M; Wood W; Haber P; Ezard N; Martinello M; Maher L; Dore GJ; Peolim L; How-Chow D; Telenta J; Harvey P; Jones S; Dunlop A; Treloar C; Samuel Y; Poeder F; Crawford S; Baxter A; Keats J; Mowat Y; Silk D; Micallef M; Tamaddoni M; Marks P; Lamoury F; Jayasinghe I; Reid H; Cunningham EB; Bartlett S; Jacka B; Erratt A; Jauncey M; Collie P; Lam T; Gilliver R; Hazelwood S; Houlihan N; Burns C; Lewis R; Morris D; Donohue K; Carthew A; Horasak N; Cherry R; Shin S; Peterson D; Sellwood T; McKeown W; Pritchard-Jones J; Smyth F; Adey S; Clark K, 2020, 'Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre- and post-universal access to direct-acting antiviral treatment in Australia: The LiveRLife study', Journal of Viral Hepatitis, vol. 27, pp. 281 - 293, http://dx.doi.org/10.1111/jvh.13233
Catlett B; Lamoury FMJ; Bajis S; Hajarizadeh B; Martinez D; Mowat Y; Cunningham PH; Jacka BP; Cloherty GA; Marks P; Dore GJ; Grebely J; Applegate TL, 2019, 'Evaluation of a hepatitis C virus core antigen assay from venepuncture and dried blood spot collected samples: A cohort study', Journal of Viral Hepatitis, vol. 26, pp. 1423 - 1430, http://dx.doi.org/10.1111/jvh.13196
Grebely J; Conway B; Cunningham EB; Fraser C; Moriggia A; Gane E; Stedman C; Cooper C; Castro E; Schmid P; Petoumenos K; Hajarizadeh B; Marks P; Erratt A; Dalgard O; Lacombe K; Feld JJ; Bruneau J; Daulouede JP; Powis J; Bruggmann P; Matthews GV; Kronborg I; Shaw D; Dunlop A; Hellard M; Applegate TL; Crawford S; Dore GJ, 2018, 'Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy', International Journal of Drug Policy, vol. 62, pp. 94 - 103, http://dx.doi.org/10.1016/j.drugpo.2018.10.004
Cunningham EB; Amin J; Feld JJ; Bruneau J; Dalgard O; Powis J; Hellard M; Cooper C; Read P; Conway B; Dunlop AJ; Norton B; Litwin AH; Hajarizadeh B; Thurnheer MC; Dillon JF; Weltman M; Shaw D; Bruggmann P; Gane E; Fraser C; Marks P; Applegate TL; Quiene S; Siriragavan S; Matthews GV; Dore GJ; Grebely J, 2018, 'Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study', International Journal of Drug Policy, vol. 62, pp. 14 - 23, http://dx.doi.org/10.1016/j.drugpo.2018.08.013
Martinello M; Bhagani S; Gane E; Orkin C; Cooke G; Dore GJ; Petoumenos K; Applegate TL; Tu E; Marks P; Pagani N; Grebely J; Nelson M; Matthews GV, 2018, 'Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection', Journal of Viral Hepatitis, vol. 25, pp. 1180 - 1188, http://dx.doi.org/10.1111/jvh.12917
Lamoury FMJ; Hajarizadeh B; Soker A; Martinez D; Quek C; Cunningham P; Catlett B; Cloherty G; Marks P; Amin J; Grebely J; Dore GJ; Applegate TL, 2018, 'Evaluation of a Hepatitis C Virus Core Antigen Assay in Plasma and Dried Blood Spot Samples', Journal of Molecular Diagnostics, vol. 20, pp. 621 - 627, http://dx.doi.org/10.1016/j.jmoldx.2018.05.010
Lamoury FMJ; Bajis S; Hajarizadeh B; Marshall AD; Martinello M; Ivanova E; Catlett B; Mowat Y; Marks P; Amin J; Smith J; Ezard N; Cock V; Hayllar J; Persing DH; Kleman M; Cunningham P; Dore GJ; Applegate TL; Grebely J, 2018, 'Evaluation of the Xpert HCV Viral Load Finger-Stick Point-of-Care Assay', Journal of Infectious Diseases, vol. 217, pp. 1889 - 1896, http://dx.doi.org/10.1093/infdis/jiy114
Grebely J; Dalgard O; Conway B; Cunningham EB; Bruggmann P; Hajarizadeh B; Amin J; Bruneau J; Hellard M; Litwin AH; Marks P; Quiene S; Siriragavan S; Applegate TL; Swan T; Byrne J; Lacalamita M; Dunlop A; Matthews GV; Powis J; Shaw D; Thurnheer MC; Weltman M; Kronborg I; Cooper C; Feld JJ; Fraser C; Dillon JF; Read P; Gane E; Dore GJ, 2018, 'Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial', The Lancet Gastroenterology and Hepatology, vol. 3, pp. 153 - 161, http://dx.doi.org/10.1016/S2468-1253(17)30404-1
Grebely J; Dalgard O; Cunningham EB; Hajarizadeh B; Foster GR; Bruggmann P; Conway B; Backmund M; Robaeys G; Swan T; Amin J; Marks PS; Quiene S; Applegate TL; Weltman M; Shaw D; Dunlop A; Hellard M; Bruneau J; Midgard H; Bourgeois S; Staehelin C; Dore GJ, 2017, 'Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study', International Journal of Drug Policy, vol. 47, pp. 177 - 186, http://dx.doi.org/10.1016/j.drugpo.2017.05.020
Midgard H; Hajarizadeh B; Cunningham EB; Conway B; Backmund M; Bruggmann P; Bruneau J; Bourgeois S; Dunlop A; Foster GR; Hellard M; Robaeys G; Thurnheer MC; Weltman M; Amin J; Marks PS; Quiene S; Dore GJ; Dalgard O; Grebely J, 2017, 'Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study', International Journal of Drug Policy, vol. 47, pp. 230 - 238, http://dx.doi.org/10.1016/j.drugpo.2017.05.040
Lamoury FMJ; Soker A; Martinez D; Hajarizadeh B; Cunningham EB; Cunningham P; Bruggmann P; Foster GR; Dalgard O; Backmund M; Conway B; Robaeys G; Swan T; Cloherty G; Marks P; Grebely J; Dore GJ; Applegate TL, 2017, 'Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse', Journal of Clinical Virology, vol. 92, pp. 32 - 38, http://dx.doi.org/10.1016/j.jcv.2017.05.007
Grebely J; Lamoury FMJ; Hajarizadeh B; Mowat Y; Marshall AD; Bajis S; Marks P; Amin J; Smith J; Edwards M; Gorton C; Ezard N; Persing D; Kleman M; Cunningham P; Catlett B; Dore GJ; Applegate TL, 2017, 'Evaluation of the Xpert HCV Viral Load point-of-care assay from venepuncture-collected and finger-stick capillary whole-blood samples: a cohort study', The Lancet Gastroenterology and Hepatology, vol. 2, pp. 514 - 520, http://dx.doi.org/10.1016/S2468-1253(17)30075-4
Cunningham EB; Hajarizadeh B; Dalgard O; Amin J; Hellard M; Foster GR; Bruggmann P; Conway B; Backmund M; Robaeys G; Swan T; Marks PS; Quiene S; Applegate TL; Weltman M; Shaw D; Dunlop A; Bruneau J; Midgard H; Bourgeois S; Thurnheer MC; Dore GJ; Grebely J; Shaw I; Siriragavan S; Horschik T; Sharma S; Eevers A; Andreassen J; Melkeraaen I; Widder N; Lesneuck K; Kotsoros B; Hazelwood S; Holland R; Axten D; Von Bibra S; Powis J; Mason K; Ryder S; Jack K; Scheidegger C; Huber C; Ferguson C; Staehelin C; Lacalamita M; Fragomeli V; Sevehon A, 2017, 'Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study', BMC Infectious Diseases, vol. 17, http://dx.doi.org/10.1186/s12879-017-2517-3
Martinello M; Gane E; Hellard M; Sasadeusz J; Shaw D; Petoumenos K; Applegate T; Grebely J; Maire L; Marks P; Dore GJ; Matthews GV, 2016, 'Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: The DARE-C II study', Hepatology, vol. 64, pp. 1911 - 1921, http://dx.doi.org/10.1002/hep.28844
Doyle JS; Grebely J; Spelman T; Alavi M; Matthews GV; Thompson AJ; Dore GJ; Hellard ME; Kaldor J; Marks P; Lloyd A; Haber P; French R; White P; Rawlinson W; Day C; Van Beek I; McCaughan G; Madden A; Dolan K; Farrell G; Crofts N; Sievert W; Baker D, 2016, 'Quality of life and social functioning during treatment of recent hepatitis C infection: A multi-centre prospective cohort', PLoS ONE, vol. 11, http://dx.doi.org/10.1371/journal.pone.0150655
Alavi M; Spelman T; Matthews GV; Haber PS; Day C; van Beek I; Walsh N; Yeung B; Bruneau J; Petoumenos K; Dolan K; Kaldor JM; Dore GJ; Hellard M; Grebely J; Marks P; Amin J; Doab A; Carroll T; Teutsch S; Li H; Oon A; Cameron B; Lloyd A; White P; Rawlinson W; Jacqueline Flynn ; Goy K; Nguyen O; von Bibra S; Ffrench R; McCaughan G; Madden A; Farrell G; Crofts N; Sievert W; Baker D; Jacka B; Pan Y; Shaw D; Sasadeusz J; Crawford D; Phung N; George J; Bloch M; Hughes B; Mollison L; Roberts S; Desmond P, 2015, 'Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C', International Journal of Drug Policy, vol. 26, pp. 976 - 983, http://dx.doi.org/10.1016/j.drugpo.2015.05.003
Hajarizadeh B; Grady B; Page K; Kim AY; McGovern BH; Cox AL; Rice TM; Sacks-Davis R; Bruneau J; Morris M; Amin J; Schinkel J; Applegate T; Maher L; Hellard M; Lloyd AR; Prins M; Geskus RB; Dore GJ; Grebely J; Lauer G; Shoukry NH; Hahn J; Shiboski S; Rice TM; Alavi M; Bouchard R; Aneja J; Teutsch S; White B; Wells B; Zang G; Matthews G; Marks P; Yeung B; Prince LE; Roy E; Bates A; Enriquez J; Chow S; McCredie L; Aitken C; Doyle J; Spelman T; Evans J, 2014, 'Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: The InC3 Study', Journal of Clinical Virology, vol. 61, pp. 430 - 434, http://dx.doi.org/10.1016/j.jcv.2014.08.027
Baker D; Alavi M; Erratt A; Hill S; Balcomb A; Hallinan R; Siriragavan S; Richmond D; Smart J; Keats J; Doong N; Marks P; Grebely J; Dore GJ, 2014, 'Delivery of treatment for hepatitis C virus infection in the primary care setting', European Journal of Gastroenterology and Hepatology, vol. 26, pp. 1003 - 1009, http://dx.doi.org/10.1097/MEG.0000000000000150
Baker D; Alavi M; Erratt A; Hill S; Balcomb A; Hallinan R; Siriragavan S; Richmond D; Smart J; Keats J; Doong N; Marks P; Grebely J; Dore GJ, 2014, 'Delivery of treatment for hepatitis C virus infection in the primary care setting', Journal of Nursing Administration, vol. 44, pp. 1003 - 1009, http://dx.doi.org/10.1097/MEG.0000000000000150
Giarda P; Avihingsanon A; Sasadeusz J; Audsley J; Marks P; Matthews G; Ruxrungtham K; Lewin SR; Crane M, 2014, 'CXCL-10, interleukin-12 and interleukin-21 are not immunological predictors of HBeAg seroconversion in HIV-1-HBV coinfection following HBV-active antiretroviral therapy', Antiviral Therapy, vol. 19, pp. 429 - 433, http://dx.doi.org/10.3851/IMP2720
Treloar C; Rance J, 2014, 'How to build trustworthy hepatitis C services in an opioid treatment clinic? A qualitative study of clients and health workers in a co-located setting', International Journal of Drug Policy, vol. 25, pp. 865 - 870, http://dx.doi.org/10.1016/j.drugpo.2014.01.011
Hellard M; Grebely J; Yeung B; Dore G; Marks P; Shaw D; Byrne M; Matthews G, 2012, 'EFFECTIVENESS OF RESPONSE-GUIDED THERAPY IN RECENT HEPATITIS C INFECTION: THE AUSTRALIAN TRIAL IN ACUTE HEPATITIS C', DRUG AND ALCOHOL REVIEW, vol. 31, pp. 33 - 33, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000311236700104&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Crawford DHG; Dore GJ; Sievert W; Cheng WSC; Weltman M; McCaughan G; Rawlinson WD; Marks P; Yoshihara M; Rizkalla B; Roberts SK, 2012, 'Early on-treatment viral load and baseline METAVIR score: Improved prediction of sustained virological response in HCV genotype 1 patients', Antiviral Therapy, vol. 17, pp. 849 - 854, http://dx.doi.org/10.3851/IMP2104
Grebely J; Matthews GV; Petoumenos K; Yeung B; Day C; Lloyd AR; Beek IV; Kaldor JM; Hellard M; Dore GJ; Haber PS; Alavi M, 2012, 'Effect of pegylated interferon-a-2a treatment on mental health during recent hepatitis C virus infection', Journal of Gastroenterology and Hepatology, vol. 27, pp. 957 - 965, http://dx.doi.org/10.1111/j.1440-1746.2011.07035.x
Avihingsanon A; Matthews GV; Lewin SR; Marks P; Sasadeusz JJ; Cooper DA; Bowden S; Locarnini SA; Dore GJ; Ruxrungtham K, 2012, 'Assessment of HBV flare in a randomized clinical trial in HIV/HBV coinfected subjects initiating HBV-active antiretroviral therapy in Thailand', AIDS Research and Therapy, vol. 9, pp. Article number 6, http://dx.doi.org/10.1186/1742-6405-9-6
Matthews G; Pham STP; Hellard M; Grebely J; Zhang L; Oon A; Marks P; Van Beek IA; Rawlinson WD; Kaldor JM; Lloyd AR; Dore GJ; White PA, 2011, 'Patterns and characteristics of Hepatitis C transmission clusters among HIV-positive and HIV-negative individuals in the Australian Trial in Acute Hepatitis C', Clinical Infectious Diseases, vol. 52, pp. 803 - 811, http://dx.doi.org/10.1093/cid/ciq200
Cheng W; Roberts S; McCaughan G; Sievert W; Weltman MD; Crawford D; Rawlinson WD; Marks P; Thommes J; Rizkalla B; Yoshihara M; Dore GJ, 2010, 'Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing', Journal of Hepatology, vol. 53, pp. 616 - 623, http://dx.doi.org/10.1016/j.jhep.2010.04.024
Grebely J; Petoumenos K; Hellard M; Matthews G; Suppiah V; Applegate TL; Yeung B; Marks P; Rawlinson WD; Lloyd AROLA; Booth D; Kaldor JM; George J; Dore GJ, 2010, 'Potential Role for Interleukin-28B Genotype in Treatment Decision-Making in Recent Hepatitis C Virus Infection', Hepatology, vol. 52, pp. 1216 - 1224, http://dx.doi.org/10.1002/hep.23850
Dore GJ; Hellard M; Matthews G; Grebely J; Haber PS; Petoumenos K; Yeung B; Marks P; Van Beek IA; McCaughan G; White PA; French R; Rawlinson WD; Lloyd AROLA; Kaldor JM; Dolan K, 2010, 'Effective treatment of injecting drug users with recently acquired hepatitis C virus infection', Gastroenterology, vol. 138, pp. 123 - 135, http://dx.doi.org/10.1053/j.gastro.2009.09.019
Grebely J; Petoumenos K; Matthews G; Haber PS; Marks P; Lloyd AROLA; Kaldor JM; Dore GJ; Hellard M; Dolan K, 2010, 'Factors associated with uptake of treatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort: The ATAHC Study', Drug and Alcohol Dependence, vol. 107, pp. 244 - 249, http://dx.doi.org/10.1016/j.drugalcdep.2009.09.015
Haber P; Hellard M; Matthews GV; Grebely J; Petoumenos K; Yeung B; Marks P; Van Beek I; Kaldor J; Dore GJ, 2009, 'TREATMENT OF RECENT HEPATITIS C VIRUS INFECTION IN A PREDOMINANTLY INJECTION DRUG USER COHORT: THE ATAHC STUDY', DRUG AND ALCOHOL REVIEW, vol. 28, pp. A27 - A27, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000270916300083&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Roberts S; Weltman M; Crawford D; Mccaughan GW; Sievert W; Cheng W; Rawlinson WD; Desmond PV; Marks P; Yoshihara M; Rizkalla B; DePamphilis J; Dore GJ, 2009, 'Impact of High-Dose Peginterferon Alfa-2A on Virological Response Rates in Patients with Hepatitis C Genotype 1: a Randomized Controlled Trial', Hepatology, vol. 50, pp. 1045 - 1055, http://dx.doi.org/10.1002/hep.23130
Chang JH; Sirivichayakul S; Avihingsanon A; Thompson A; Revill P; Iser D; Slavin J; Buranapraditkun S; Marks P; Matthews G; Cooper DA; Kent SJ; Cameron P; Sasadeusz J; Desmond PV; Locarnini S; Dore GJ; Ruxrungtham K; Lewin S, 2009, 'Impaired Quality of the Hepatitis B Virus (HBV)-Specific T-Cell Response in Human Immunodeficiency Virus Type 1-HBV Coinfection', Journal of Virology, vol. 83, pp. 7649 - 7658, http://dx.doi.org/10.1128/JVI.00183-09
Lewin S; Ribiero R; Avihingsanon A; Bowden S; Matthews G; Marks P; Locarnini S; Ruxrungtham K; Perelson AS; Dore GJ, 2009, 'Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1-hepatitis B virus coinfected individuals: Similar effectiveness of lamivudine, tenofovir, or combination therapy', Hepatology, vol. 49, pp. 1113 - 1121, http://dx.doi.org/10.1002/hep.22754
Matthews G; Hellard M; Haber P; Yeung B; Marks PB; Baker D; McCaughan G; Sasadeusz J; White PA; Rawlinson WD; Lloyd AR; Kaldor JM; Dore GJ, 2009, 'Characteristics and treatment outcomes among HIV-infected individuals in the Australian Trial in acute hepatitis C', Clinical Infectious Diseases, vol. 48, pp. 650 - 658, http://dx.doi.org/10.1086/596770
Matthews G; Seaberg E; Dore GJ; Bowden S; Lewin S; Sasadeusz J; Marks P; Goodman Z; Philp F; Tang Y; Locarnini S; Thio C, 2009, 'Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individuals', AIDS, vol. 23, pp. 1707 - 1715, http://dx.doi.org/10.1097/QAD.0b013e32832b43f2
Matthews G; Avihingsanon A; Lewin S; Amin J; Rerknimitr R; Petcharapirat P; Marks PB; Sasadeusz J; Cooper DA; Bowden S; Locarnini S; Ruxrungtham K; Dore GJ, 2008, 'A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naive individuals in Thailand', Hepatology, vol. 48, pp. 1062 - 1069, http://dx.doi.org/10.1002/hep.22462
Burmeister B; Smithers M; Gebski V; Denham J; Devitt P; Ackland S; Findlay M; Dhillon H; Stockler M; Coates A; Matthews J; Simes J; Beller E; Fitzgerald L; Gray E; Dodds H; Marks P; Hayden P; Erratt A; Monro C; Pike R; Walpole E; Gotley D; Thomson D; Harvey J; Martin I; Burmeister E; Jamieson G; Borg M; Yeoh E; Olver I; Caruso D; Game P; Joseph D; Spry N; Minchin D; Cameron F; Faulkner K; Einhorn S; Dewar J; Gillies J; Johnson C; Kilmurray J; Neely M; Carmody M; Mackintosh J; Millar J; O'Brien P; Schwartz M; Smith R; Woods S; Nathanson L; O'Loughlin B; Grimes D; Cheuk R; Dickie G; Keller J; Archer S; Bayliss E; Gray B; Trotter J; Ransom D; Shepherd J; Stone C; Thompson I; Guiney M; Henderson M; Thomas R; Kian M; Ngan S; Rischin D; Walcher V; Zalcberg J; North J; Costello S; Perez D; Whitely D; Wyllie A; Avramovic J; Donnolly P; Fon P; Collins M; McIntosh R; Melville P; Bell R; Kirrof G; Harris I; McLennan R; Monro W; Aroney R; Falconer K; Cullingford G; Davidson A; Randell C; Berry M; Delaney G; Moylan E; Burns D; Goldstein D; Zissiadis M, 2005, 'Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: A randomised controlled phase III trial', Lancet Oncology, vol. 6, pp. 659 - 668, http://dx.doi.org/10.1016/S1470-2045(05)70288-6
Hajarizadeh B; Grebely J; Byrne M; Marks P; Amin J; Butler T; Vickerman P; Martin NK; Mchutchison JG; Brainard DM; Treloar C; Lloyd AR; Dore GJ, 2017, 'Incidence of hepatitis C virus infection in two maximum-security prisons in New South Wales, Australia: the SToP-C study', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, Amsterdam, NETHERLANDS, pp. S274 - S274, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Amsterdam, NETHERLANDS, 19 April 2017 - 23 April 2017, http://dx.doi.org/10.1016/S0168-8278(17)30862-0
Hajarizadeh B; Grebely J; Byrne M; Marks P; Butler T; Amin J; Vickerman P; Martin NK; McHutchison JG; Brainard DM; Treloar C; Lloyd AR; Dore G, 2016, 'Hepatitis C virus exposure, infection and associated risk behaviours in two maximum-security prisons in New South Wales, Australia', in HEPATOLOGY, WILEY, Boston, MA, pp. 385A - 386A, presented at 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Boston, MA, 11 November 2016 - 15 November 2016, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000385493802052&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Matthews GV; Grebely J; Hellard M; Yeung B; Marks P; Rawlinson W; Kaldor J; Dore G, 2010, 'DIFFERENCES IN EARLY VIROLOGICAL DECLINE IN INDIVIDUALS TREATED WITHIN THE AUSTRALIAN TRIAL IN ACUTE HCV SUGGEST A POTENTIAL BENEFIT FOR THE USE OF RIBAVIRIN', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, Vienna, AUSTRIA, pp. S28 - S28, presented at 45th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Vienna, AUSTRIA, 14 April 2010 - 18 April 2010, http://dx.doi.org/10.1016/S0168-8278(10)60062-1
Matthews GV; Grebely J; Hellard M; Yeung B; Marks P; Rawlinson W; Kaldor J; Dore GJ, 2010, 'WEEK 4 HCV RNA IS THE OPTIMAL PREDICTOR OF SVR IN BOTH HIV POSITIVE AND NEGATIVE SUBJECTS WITHIN THE AUSTRALIAN TRIAL IN ACUTE HCV', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, Vienna, AUSTRIA, pp. S116 - S116, presented at 45th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Vienna, AUSTRIA, 14 April 2010 - 18 April 2010, http://dx.doi.org/10.1016/S0168-8278(10)60278-4
Dore GJ; Hellard M; Matthews G; Grebely J; Haber PS; Petoumenos K; Yeung B; Marks P; van Beek I; McCaughan GW; White PA; Ffrench RA; Rawlinson W; Lloyd AR; Kaldor J, 2009, 'TREATMENT OF RECENT HEPATITIS C VIRUS INFECTION IN A PREDOMINANTLY INJECTION DRUG USER COHORT: THE ATAHC STUDY', in HEPATOLOGY, JOHN WILEY & SONS INC, Boston, MA, pp. 723A - 723A, presented at 60th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Boston, MA, 30 October 2009 - 03 November 2009, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000270456000887&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Matthews G; Grebely J; Pham ST; Hellard M; Marks P; Rawlinson W; Kaldor J; Lloyd AR; White PA; Dore GJ, 2009, 'EPIDEMIOLOGY OF RECENTLY ACQUIRED HEPATITIS C VIRUS (HCV) INFECTION IN HCV AND HCV/HIV INFECTED PARTICIPANTS IN THE ATAHC STUDY', in HEPATOLOGY, JOHN WILEY & SONS INC, Boston, MA, pp. 668A - 668A, presented at 60th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Boston, MA, 30 October 2009 - 03 November 2009, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000270456000775&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Matthews G; Avihingsanon A; Lewin S; Sasadeusz J; Marks P; Revill PA; Ayres A; Bow-den S; Locarnini S; Thio CL; Ruxrungtham K; Dore GJ, 2008, 'TENOFOVIR-BASED HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) IS ASSOCIATED WITH HIGH RATES OF HBV DNA SUPPRESSION AND HBEAG SEROCONVERSION IN THAI HIV-HBV COINFECTED PATIENTS', in HEPATOLOGY, JOHN WILEY & SONS INC, San Francisco, CA, pp. 712A - 713A, presented at 59th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, San Francisco, CA, 31 October 2008 - 04 November 2008, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000259757401290&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Crawford D; Robertson SL; Weltman MD; Cheng W; Sievert W; McCaughan G; Desmond PV; Alston A; DePamphilis J; Marks PB; Dore GJ, 2008, 'Baseline factors associated with rapid and early virological responses in HCV genotype 1 patients treated with induction dosing of pegylated interferon: The CHARIOT study', in Journal of Hepatology, Elsevier Science BV, Amsterdam, Netherlands, pp. S290 - S291, presented at Journal of Hepatology
Matthews G; Avihingsanon A; Lewin S; Sasadeusz J; Marks PB; Revill P; Ayres A; Bow-den S; Locarnini S; Thio C; Ruxrungtham K; Dore GJ, 2008, 'TENOFOVIR-BASED HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) IS ASSOCIATED WITH HIGH RATES OF HBV DNA SUPPRESSION AND HBEAG SEROCONVERSION IN THAI HIV-HBV COINFECTED PATIENTS', in Hepatology, John Wiley & Sons Inc, Hoboken, NJ, USA, pp. 906 - 907, presented at Hepatology
Hellard M; Matthews G; Petoumenos K; Grebely J; Haber PS; Van Beek IA; Marks P; Lloyd AR; Kaldor JM; Dore GJ, 2008, 'Factors associated with uptake of treatment for acute and early chronic hepatitis C virus infection', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A344 - A344, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000264953600030&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
Matthews G; Grebely J; White PA; Renkin M; Marks PB; Ffrench R; Rawlinson WD; Kaldor JM; Hellard M; Lloyd AR; Dore GJ, 2008, 'INCIDENCE AND RISK FACTORS FOR HCV SUPERINFECTION AND REINFECTION IN INDIVIDUALS TREATED FOR ACUTE/EARLY CHRONIC HCV INFECTION', in Hepatology, John Wiley & Sons Inc, Hoboken, NJ, USA, pp. 1844 - 1845, presented at Hepatology, San Francisco, CA, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000259757402521&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
Matthews G; White PA; Hellard M; Grebely J; Marks P; Yeung B; Kaldor JM; Lloyd AR; Danta M; Dore GJ, 2008, 'Evidence of sexual transmission of hepatitis C virus infection among HIV-positive men who have sex with men in the Australian trial in acute hepatitis C (ATAHC) study', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A365 - A366, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000264953600081&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
Jones T; Marks P; Connelly C; Warner S; Fragomeli V; Walker PJ; Ferguson CM; Dore GJ, 2008, 'Predictors of HCV treatment uptake and clinical trial participation among patients newly referred for HCV infection: the HCV clinical audit study', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A241 - A241, presented at Journal of Gastroenterology and Hepatology, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000259960100133&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
Matthews G; Hellard M; Haber PS; Yeung B; Marks PB; Sasadcusz J; Baker DA; McCaughan G; White PA; Rawlinson WD; Lloyd AR; Kaldor JM; Dore GJ, 2008, 'Frequency of RVR and its utility as a predictor of treatment outcome in individuals treated within the Australian Trial in Acute Hepatitis c (ATAHC)', in Journal of Hepatology, Elsevier Science BV, Amsterdam, Netherlands, pp. S303 - S303, presented at Journal of Hepatology, Milan, ITALY, http://dx.doi.org/10.1016/S0168-8278(08)60812-0
Matthews G; Hellard M; Haber PS; Yeung B; Marks P; Rawlinson WD; Lloyd AR; Kaldor JM; Dore GJ, 2008, 'Frequency of rapid virological response and its utility as a predictor of treatment outcome in individuals treated within the Australian trial in acute hepatitis C (ATAHC)', in Journal of Gastroenterology and Hepatology, Blackwell Publishing Asia, Carlton, Victoria, Australia, pp. A337 - A337, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000264953600012&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a
Byrne M; Hajarizadeh B; Dore GJ; Treloar C; Marks P; Milat A; Bowman J; McGrath C; Bath N; Calder I; Lagios K; Grebely J; Lloyd A, 2017, 'A framework for hepatitis C virus treatment as prevention in the prison setting: the SToP-C implementation toolkit', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, Amsterdam, NETHERLANDS, Vol. 66, pp. S495 - S495, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Amsterdam, NETHERLANDS, 19 April 2017 - 23 April 2017, http://dx.doi.org/10.1016/S0168-8278(17)31387-9
Lamoury F; Soker A; Martinez D; Hajarizadeh B; Cunningham E; Bruggmann P; Foster G; Dalgard O; Conway B; Robaeys G; Swan T; Backmund M; Marks P; Grebely J; Dore GJ; Applegate TL, 2016, 'HEPATITIS C VIRUS CORE ANTIGEN: A SIMPLIFIED TREATMENT MONITORING TOOL, INCLUDING FOR POST-TREATMENT RELAPSE', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, Barcelona, SPAIN, Vol. 64, pp. S625 - S626, presented at EASL International Liver Congress, Barcelona, SPAIN, 13 April 2016 - 17 April 2016, http://dx.doi.org/10.1016/S0168-8278(16)01163-6
Grebely J; Dalgard O; Conway B; Foster G; Bruggmann P; Backmund M; Robaeys G; Swan T; Hajarizadeh B; Amin J; Marks P; Quiene S; Weltman M; Shaw D; Dunlop A; Hellard M; Bruneau J; Bourgeois S; Thurnheer C; Dore GJ, 2015, 'EFFICACY OF RESPONSE-GUIDED PEGYLATED INTERFERON AND RIBAVIRIN THERAPY FOR PEOPLE WHO INJECT DRUGS WITH HCV GENOTYPE 2/3 INFECTION: THE ACTIVATE STUDY', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, Vienna, AUSTRIA, Vol. 62, pp. S657 - S657, presented at 50th International Liver Congress of the European-Association-for-the-Study-of-the-Liver, Vienna, AUSTRIA, 22 April 2015 - 26 April 2015, http://dx.doi.org/10.1016/S0168-8278(15)31050-3
Grebely J; Dalgard O; Conway B; Cunningham E; Bruggmann P; Hajarizadeh B; Amin J; Marks P; Quiene S; Applegate TL; Swan T; Byrne J; Lacalamita M; Dunlop AJ; Bruneau J; Hellard ME; Matthews GV; Powis J; Shaw D; Thurnheer CM; Weltman M; Kronborg I; Cooper C; Feld JJ; Fraser C; Litwin A; Dillon J; Read P; Gane E; Dore GJ, 2017, 'Efficacy and safety of sofosbuvir/velpatasvir in people with chronic hepatitis C virus infection and recent injecting drug use: the SIMPLIFY study', in JOURNAL OF HEPATOLOGY, ELSEVIER SCIENCE BV, Amsterdam, NETHERLANDS, Vol. 66, pp. S513 - S513, presented at International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Amsterdam, NETHERLANDS, 19 April 2017 - 23 April 2017, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000401056601271&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1